Sign in to view content

Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results

Peter J. Kertes, MD, FRCS(C)

Video
Published 2020

Related

What Is the Clinical Significance of Improving Diabetic Retinopathy for Vision Outcomes? A Meta-Analysis of 5 Ranibizumab Trials
Sophie Jane Bakri, MD
Annual Meeting Talks
2021
Prospective Evaluation of Pain and Inflammation Following Injection of Aflibercept or Ranibizumab in Patients With Diabetic Macular Edema: SOLAR Study
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2018
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more